Last update 01 Nov 2024

PTGFR x β2-adrenergic receptor x β1-adrenergic receptor

Last update 01 Nov 2024

Basic Info

Drugs associated with PTGFR x β2-adrenergic receptor x β1-adrenergic receptor

Carteolol Hydrochloride/Latanoprost

Target

PTGFR x β1-adrenergic receptor x β2-adrenergic receptor

Mechanism

PTGFR agonists [+2]

Active Org.

Otsuka Holdings Co., Ltd. [+2]

Originator Org.

Otsuka Pharmaceutical Co., Ltd.

Active Indication

Glaucoma [+1]

Inactive Indication-

Drug Highest PhaseApproved

First Approval Ctry. / Loc.

First Approval Date28 Sep 2016

Clinical Trials associated with PTGFR x β2-adrenergic receptor x β1-adrenergic receptor

CTR20221401 / Active, not recruitingPhase 3

一项评价OPC-1085EL 滴眼液治疗原发性开角型青光眼或高眼压症中国受试者的有效性及安全性的III期多中心、随机、单盲（评价者盲）、平行、阳性对照临床试验

[Translation] A Phase III multicenter, randomized, single-blind (evaluator-blind), parallel, positive-controlled clinical trial to evaluate the efficacy and safety of OPC-1085EL eye drops in the treatment of primary open-angle glaucoma or ocular hypertension in Chinese subjects

主要目的以原发性开角型青光眼或高眼压症中国受试者为对象，评价OPC-1085EL 滴眼液与0.005％拉坦前列素滴眼液相比的降眼压作用的优效性。次要目的比较OPC-1085EL滴眼液与0.005％拉坦前列素滴眼液使用的安全性。

[Translation]

Primary objective To evaluate the superiority of OPC-1085EL eye drops in lowering intraocular pressure compared with 0.005% latanoprost eye drops in Chinese subjects with primary open-angle glaucoma or ocular hypertension. Secondary objective To compare the safety of OPC-1085EL eye drops and 0.005% latanoprost eye drops.

Start Date27 Sep 2022

Sponsor / Collaborator

Teika Pharmaceutical Co., Ltd.

[+2]

NCT05583474 / RecruitingPhase 3

A Phase III, Multi-center, Randomized, Single-blind (to Evaluator), Parallel, and Positive-controlled Clinical Trial Evaluating the Efficacy and Safety of OPC-1085EL Ophthalmic Solution in the Treatment of Primary Open Angle Glaucoma or Ocular Hypertension in Chinese Subjects

It is a phase III, multi-center, randomized, single-blind (to evaluator), parallel, and positive-controlled clinical trial evaluating the efficacy and safety of OPC-1085EL in the treatment of primary open angle glaucoma or ocular hypertension in Chinese subjects. It is planned that 240 subjects (120 in each group) will be randomly assigned to receive OPC-1085EL or 0.005% latanoprost ophthalmic solution (latanoprost) at a ratio of 1:1.

Start Date27 Sep 2022

Sponsor / Collaborator

Otsuka Beijing Research Institute

JPRN-JapicCTI-142489 / Unknown statusPhase 1

A single-center, randomized, active-controlled study to determine the pharmacokinetics of OPC-1085EL ophthalmic solution in healthy adult male subjects (Phase 1 study)

Start Date01 Apr 2014

Sponsor / Collaborator

Otsuka Pharmaceutical Co., Ltd.

100 Clinical Results associated with PTGFR x β2-adrenergic receptor x β1-adrenergic receptor

100 Translational Medicine associated with PTGFR x β2-adrenergic receptor x β1-adrenergic receptor

0 Patents (Medical) associated with PTGFR x β2-adrenergic receptor x β1-adrenergic receptor

Literatures (Medical) associated with PTGFR x β2-adrenergic receptor x β1-adrenergic receptor

01 Oct 1994·Circulation

More on paradoxical pressor effects of nonselective beta-blockers.

Letter

Author: T. J. M. Cleophas ; F. H. W. Kauw

A pressor effect of nonselective beta-blockers has been reported from the very beginning [1]. It was observed in patients with emotional stress, low renin hypertension and increased sympathetic activity [2], also in patients with untreated pheochromocytoma [3], with clonidine withdrawal [4], abuse of cocaine [5], and subcutaneous administration of epinephrine [6]. The most consistent finding in these reports was the situation of increased sympathetic activity. It was hypothesized that alpha-receptor-mediated vasoconstriction unopposed by beta-2-receptor-mediated vasodilation might be responsible. In situations of increased sympathetic activity this mechanism might override the otherwise hypotensive activity of nonselective beta-blockers. In order to test this hypothesis investigators started to design controlled trials comparing beta-1-selective and nonselective beta-blockers. On the one hand beta-1-selective blockers have a weak binding potency at the beta-2-receptor site and are, thus, less likely to produce this pressor effect. On the other hand, however, the selectivity is not absolute, but dose-dependent (e.g., metoprolol and atenolol lose their beta-1-selectivity with incremental doses [7]). Correspondingly, the different effects of beta-1-selective drugs on peripheral vascular resistance compared to nonselective compounds seem to be dose dependent [8]. Finally, even the heart does contain not only socalled cardioselective beta-1 but also otherwise vasodilative beta-2-adrenergic receptors [9].

Analysis

Perform a panoramic analysis of this field.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

PTGFR x β2-adrenergic receptor x β1-adrenergic receptor

Basic Info

Related

Analysis